Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J A McCaffreyD F Bajorin

Abstract

A phase II trial of docetaxel was conducted to assess its efficacy and toxicity in patients with advanced transitional-cell carcinoma (TCC) who had failed to respond to prior cisplatin-based therapy. Thirty assessable patients who had failed to respond to or relapsed after one prior cisplatin-containing regimen were treated with docetaxel 100 mg/m2 over 1 hour, every 21 days. All patients were premedicated with dexamethasone and diphenhydramine to reduce allergic reactions. Reductions of subsequent doses were made for severe hematologic toxicity. Prophylactic hematopoietic growth factors were not used. Four of 30 patients (13.3%; 95% confidence interval [CI], 3.8% to 30.7%) demonstrated a partial response (PR), with durations of response ranging from 3 to 8 months. The estimated median survival duration for all patients is 9 months (95% CI, 6 to 12 months) with a median follow-up time of 14 months (range, 1 to 27). Hematologic toxicity included anemia, thrombocytopenia, neutropenia, and febrile neutropenia. Nonhematologic toxicity included alopecia and mucositis. Fluid retention was not observed and cutaneous toxicity was mild and infrequent. Dose reductions were necessary for adverse events in 18 patients (60%). Docetaxel is a...Continue Reading

Associated Clinical Trials

Sep 20, 2012·Andrea Apolo, M.D.Andrea Apolo, M.D.

Citations

Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F BajorinM G Boyle
Dec 21, 2000·Current Oncology Reports·M J Edelman
Jan 5, 2002·Expert Opinion on Investigational Drugs·Hideyuki Akaza
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BamiasUNKNOWN Hellenic Cooperative Oncology Group
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BamiasM A Dimopoulos
Nov 30, 2005·The Oncologist·Matthew D Galsky
Jul 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J SweeneyDonald S Kaufman
Dec 6, 2006·Investigational New Drugs·Matthew D GalskyDean F Bajorin
Apr 25, 2007·Japanese Journal of Clinical Oncology·Hideyuki AkazaUNKNOWN Japanese Gemcitabine Study Group
Mar 28, 2008·Expert Opinion on Investigational Drugs·Adrian Yun-San YipLouis Wing-Cheong Chow
Dec 22, 2007·Expert Review of Anticancer Therapy·Guru SonpavdeThomas E Hutson
Feb 13, 2009·Japanese Journal of Clinical Oncology·Takahito SuyamaMasayuki Maruoka
Jun 25, 2009·Current Opinion in Urology·Mark Bachner, Maria De Santis
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntJonathan E Rosenberg
Nov 30, 2010·Expert Review of Anticancer Therapy·Gopa IyerDean F Bajorin
Jul 1, 2009·Therapeutic Advances in Medical Oncology·Guru SonpavdeJonathan E Rosenberg
Jul 3, 2013·Cancer Control : Journal of the Moffitt Cancer Center·Shilpa Gupta, Amit Mahipal
Jul 25, 2014·Current Oncology Reports·Estrella M Carballido, Jonathan E Rosenberg
Jun 26, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Koji MitsuzukaYoichi Arai
May 20, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Qing LiLin Gao
Mar 18, 2016·Current Oncology Reports·Tracy L Rose, Matthew I Milowsky
May 10, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arjun Vasant Balar
Jul 20, 2017·Current Medical Research and Opinion·J Mark StephensChristopher S Hollenbeak
Oct 11, 2017·Expert Review of Clinical Pharmacology·Michael Crist, Arjun Balar
Nov 10, 2018·Expert Opinion on Pharmacotherapy·Aly-Khan A Lalani, Guru P Sonpavde
Jul 2, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francisco E Vera-BadilloChristopher M Booth
Jul 25, 2019·The New England Journal of Medicine·Yohann LoriotUNKNOWN BLC2001 Study Group
Dec 6, 2019·Therapeutic Advances in Medical Oncology·Chiara CasadeiUgo De Giorgi
Mar 29, 2000·BJU International·C N Sternberg, F Calabrò
Mar 5, 2002·British Journal of Cancer·X Garcia del MuroJ R Germá
Apr 9, 2001·Cancer Investigation·D J Vaughn, S B Malkowicz
Aug 27, 2002·Current Treatment Options in Oncology·Fabio Calabrò, Cora N Sternberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D F BajorinG Higgins
International Journal of Urology : Official Journal of the Japanese Urological Association
Alejandro Sousa-EscandonJose R Mel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jinxing LiChristopher J Sweeney
© 2021 Meta ULC. All rights reserved